Battery recycling to become $10 billion business in 2015
A battery is never big. Small as it is, a dry cell buried in the earth will influence up to a square meter area. Our annual consumption of batteries has caused enormous damages to the earth. Also, metals and organic solutions contained in the battery are harmful to the human health. The impact on the human body depends on the metals.
According to www.energy.com.tw, methyl mercury biotransformed from mercury does great harm to central nervous system. Once absorbed into the human body, the metal lead is hard to leave and will affect and hurt the working of the human nerve system, kidney and circulatory system. As for cadmium, it is easy to cause emphysema, osteoporosis as well as liver diseases.
Therefore, for the sake of environmental protection and human health, consumers and battery manufacturers must work hard together to recycle batteries so that we cannot only enjoy an endless power supply but also do our bit for the environmental protection of the earth.
On the industry side, companies need to pay attention to environmental requirements from global governments, the recycling cost of used batteries and reusable materials. Although the above-mentioned elements add costs for electric car makers, new business opportunities also rise.
Inertial MEMS accelerometers That are 1000 Times more Sensitive will benefit applications such as bridge, infrastructure and seismic monitoring
A MEMS accelerometer is a sensor that can be used to measure vibration, shock or change in velocity. By deploying many of these detectors as part of a complete sensor network, HP will enable real-time data collection, management evaluation and analysis. This information empowers people to make better, faster decisions, and take subsequent action to improve safety, security and sustainability for a range of applications, such as bridge and infrastructure health monitoring, geophysical mapping, mine exploration and earthquake monitoring.
The HP sensing technology enables a new class of ultrasensitive, low-power MEMS accelerometers. Up to 1,000 times more sensitive than high-volume, commercial products, sensors based on this technology can achieve noise density performance in the sub 100 nano-g per square root Hz range to enable dramatic improvements in data quality. The MEMS device can be customized with single or multiple axes per chip to meet individual system requirements.
The sensing technology is a key enabler of HP’s vision for a new information ecosystem, the Central Nervous System for the Earth (CeNSE). Integrating the devices within a complete system that encompasses numerous sensor types, networks, storage, computation and software solutions enables a new level of awareness, revolutionizing communication between objects and people.
“With a trillion sensors embedded in the environment – all connected by computing systems, software and services – it will be possible to hear the heartbeat of the Earth, impacting human interaction with the globe as profoundly as the Internet has revolutionized communication,” said Peter Hartwell, senior researcher, HP Labs.
Modfied HIV Delivered Gene Therapy Could Treat Many Diseases
In a pilot study of two patients monitored for two years, an international team of researchers slowed the onset of the debilitating brain disease X-linked adrenoleukodystrophy (ALD) using a lentiviral vector to introduce a therapeutic gene into patient’s blood cells. Although studies with larger cohorts of patients are needed, these results suggest that gene therapy with lentiviral vectors, which are derived from disabled versions of human immunodeficiency virus (HIV), could potentially become instrumental in treating a broad range of human disorders
Other Gene Therapy Success and Progress
Lungs too damaged for use in transplant operations may be salvageable through a gene-based technique, doubling or tripling the supply of organs.
The flawed lungs could be removed from donors’ bodies after death and repaired using the gene IL-10, which lowers inflammation. 1800 people in the US are awaiting lung transplants.
Gene Therapy helps treat a form of blindness The condition is known as Leber’s congenital amaurosis and there are 2000 people in the US who have it.
A number of companies are developing gene therapies and 320 trials are under way or cleared to begin by U.S. regulators, said Karen Riley, a U.S. Food and Drug Administration spokeswoman. Genzyme Corp. of Cambridge, Massachusetts, will begin a human trial using gene therapy next year to treat macular degeneration, the leading form of age-related vision loss, said John Lacey, a Genzyme spokesman
In the new trial, reported today in the journal Science Translational Medicine, Bechir Jarraya and colleagues at the Molecular Imaging Research Center in Fontenay-aux-Roses, France, mimicked Parkinson’s in monkeys by giving them a neurotoxin that causes movement problems characteristic of the disorder. The researchers then injected three genes involved in dopamine production into the brains of the monkeys, as well as specially designed probes to measure dopamine levels in the brain, monitoring the animals for up to three and a half years. The gene therapy restored concentrations of dopamine in the brain, corrected movement problems, and prevented dyskinesias–without any severe adverse side effects. An early stage human clinical trial using the same dopamine gene therapy approach is now underway.
The Modified HIV Gene Therapy
The healthy ALD protein was expressed in about 15 percent of blood cells, yet surprisingly this low level was sufficient to slow brain disease in ALD. “This percentage of correction will not be sufficient for all diseases,” warns Aubourg. “There is a lot of work to be done to make this gene therapy vector more powerful, less complicated, and less expensive. This is only the beginning,” he said.
Gene therapy is not without serious risks. Like other retrovirus vectors, the HIV-derived lentivirus vector is tasked with inserting the therapeutic gene in the chromosomes of the patients’ cells. In a worst case scenario, this action could disturb the biology of the cells and patients could end up with leukemia; this outcome has occurred in past gene therapy trials. “The HIV-derived lentivirus vector basically has this same risk, although the design of the vector makes patients less prone to this side effect,” said Aubourg.
Wrong Diagnosis has statistics on ALD
Prevalance Rate: approx 1 in 20,000 or 0.00% or 13,600 people in USA
Wikipedia on Adrenoleukodystrophy
Adrenoleukodystrophy (ALD) (also known as “Addison-Schilder Disease,” “Siemerling-Creutzfeldt Disease,” and “Schilder’s disease”) is a rare, inherited disorder that leads to progressive brain damage, failure of the adrenal glands and eventually death. ALD is one disease in a group of inherited disorders called leukodystrophies. Adrenoleukodystrophy progressively damages the myelin, a complex fatty neural tissue that insulates many nerves of the central and peripheral nervous systems, eventually destroying it. Without myelin, nerves are unable to conduct an impulse, leading to increasing disability as myelin destruction increases and intensifies.
FURTHER READING
NY Times: For Gene Therapy, Seeing Signs of a Resurgence
Legislative update – Sept. 2009 — REACH, RoHS2
Summary
The legal obligations within the REACH Regulations and the potential impact of the so called “RoHS2” proposals dominate the legislative scene at present. Also, obligations are starting to filter through as part of the eco design/energy using Products Directive that monitors energy efficiency throughout a products life cycle. Going-forward, the scope of this directive will become more diverse to encompass energy related products.
Industry, and the design engineer, needs to be aware of developments and the potential impact on their companies.
REACH
Regulation 1907/2006, the Regulation, Evaluation, Authorisation -and restriction-of Chemicals (REACH) entered into force on 1 June 2007 after almost 8 years of debate and covering some 849 pages of regulation.
The only census on chemicals, taken in 1981, highlighted that 100,106 substances were placed on the market. Of those used, manufactured or imported at levels of 1000 tonnes or more, 21 percent had no safety data at all while a further 65 percent provided insufficient safe use data. Only 3 percent had been fully tested.
At the same time, instances of allergies, asthma, certain types of cancer and reproductive disorders were on the increase in Europe. Skin diseases alone resulted in the loss of 3 million working days per year.
Driven by the obligatory flow of safety data throughout the supply chain, REACH seeks to provide protection to health and the environment.
The biggest challenge to industry to date has been around the collection of data advising where a so called Substance of Very High Concern (SVHC) is present in a product, known as an article in the regulations, at a level of 0.1% by weight of the total article.
As a minimum obligation the name of the substance along with supporting safe use data must flow downstream through the supply chain.
Substances that are categorised as SVHC include those that are carcinogenic, mutagenic or toxic for reproduction. Also, substances that are persistent, liable to bio-accumulate and toxic, and finally “others” such as endocrine disrupters that can have a particular impact on aquatic life.
Back in October 2008, the first batch of 15 substances of very high concern was published by the European Chemicals Agency and, the following January, seven of these were earmarked for a consultation on whether or not they should be subject to a very costly “authorisation of use” requirement. These seven were approved and the European Commission will determine the date when these will be added to Annex XIV.
These obligations will then enter into force some 42-48 months later on what is known as the sunset date. Where such an authorisation is approved, downstream users can only use these substances for the use that they have been authorised for and they can only be purchased from the company granted the authorisation.
The REACH data collection has resulted in the circulation of hundreds of “standard letters” in a multitude of formats. Many manufacturers have refused to reply to the ad-hoc requests they receive preferring to promote websites or central databases (these have been slow to develop).
Guidance on the regulation encourages a more pro-active approach rather than simply providing a link to a website. Likewise, there have been many random requests for information that is not obligatory such as pre-registration details and RoHS style certificates of compliance.
Future batches of SVHCs will be published on an on-going basis, with the next expected early 2010, so REACH will not be a box that can be ticked as complete for several years to come.
“RoHS2”
Looking back the Restriction of Hazardous Substances (RoHS) Directive 2002/95 entered into force on 1 July 2006. It featured six restricted substances across eight broad categories of product pulled from the 10 categories in the Waste Electrical and Electronic Equipment (WEEE) Directive. There were 29 exemptions to assist manufacturers and design engineers where no viable alternative was available and a whole raft of “grey” definitions that required clarity.
“RoHS2” proposals look to move the directive forward and provide greater clarity. However, some of its provisions will potentially have cost and resource issues for industry.
The proposals recommend that the two remaining categories from the original WEEE categories, namely medical devices and monitoring and control instruments be added to the scope from 2014 (in-vitro diagnostics from 2016 and industrial “test” equipment in 2017). These were originally omitted from the directive due to reliability concerns over the use of lead-free solder.
While there are no substances actually restricted under the proposals, four are recommended for priority assessment. Three plasticisers used in a variety of applications and a flame retardant may well be restricted. Ironically, the substances, BBP, DBP, DEHP and HBCDD are four of the seven subject to authorisation of use under the REACH Regulations.
The fate of these substances under RoHS will be open to consultation after the revised directive comes into scope sometime in 2011-2012. Either way, any restriction under RoHS will probably be sooner than under the REACH process and the analysis is unlikely to be done twice.
Under a separate review by European Commission consultants, 29 exemptions will continue under the proposals, many with amended wording for clarity, 6 will be withdrawn and one new one will be granted. These could come into force next year and that will be followed by a transposition period of, on average, 18 months allowing manufacturers the time to comply.
In addition, a further six exemptions were added in June 2009 that had been proposed a year earlier.
RoHS2 also clarifies definitions such as equipment within out of scope equipment, spare parts and military where the latter clearly does not include dual use equipment.
A standard, and rigid declaration of conformity appears in annex 7 and will replace the multitude of different certificates, statements and compliance documents under the original legislation.
There now appears to be no scope for qualifying statements such as “so far as we are aware” and “to the best of our knowledge”.
It is proposed that RoHS will become a CE mark directive placing responsibilities on manufacturers, importers and distributors. There are many requirements including building technical files and keeping for 10 years, ensuring products comply, that they are supplied with the CE mark and the manufacturer or importer is identified on the product. Sample testing should also be carried out where appropriate, and corrective action is undertaken where product is found to be non compliant.
Finally under the proposals, the broad product categories and list of indicative products move from the WEEE Directive and sit in annex 1 and 2 of the RoHS Directive.
The terminology “RoHS2” is unofficial and is used simply to highlight the proposed changes to the original directive.
Energy using Products
Directive 2005/32/EC, Energy using Products, entered into force on 11 August 2007.
The main aim is to monitor energy efficiency throughout the life cycle of a product from the mining of raw material right through to recycling at end-of-life.
The focus is clearly on the design phase of the product since it is considered that this is the determining stage affecting the resources used in a product.
The directive does not apply to means of transport (planes, cars etc) but, apart from this, the scope is deliberately broad covering, in principle, any product which when in use depends on, generates, transfers or measures energy (electricity, fossil fuel or renewable).
Obligations on manufacturers will result from a series of specific “implementing measures” the first of which was adopted in January 2009.
The criteria required before a product can be considered for assessment is that is that it must sell more than 200,000 units per year in the European Union, have a significant environmental impact and present considerable potential for improvement. The latter is important as the target is for a 20% improvement in energy efficiency by 2020.
During phase one, studies were commission on 20 broad product categories ranging from water heaters, televisions and lighting, through to imaging equipment and personal computers.
Beyond that, a further 17 categories have been highlighted from ovens and hobs, machine tools and air-conditioning equipment through to transformers and networking equipment.
Among the first obligations to come in to force were energy efficiency improvements covering standby and off-mode losses, simple converter boxes for digital television, external power supplies and office, street and domestic lighting.
However, the European Parliament has now adopted the European Commission’s (EC) proposal to widen the scope of the directive to include energy related products. Until now the Energy using Products Directive was limited to products that consume energy during use such as boilers, computers, televisions, industrial fans and light bulbs.
However, many products have an indirect impact on the energy in use such as water using devices, taps and showerheads for example, and double glazing windows or insulating material.
Improvement in design could clearly result in the significant saving of energy.
For example, water saving taps and shower heads reduce water consumption and therefore the amount of energy used for hot water.
Under the EuP Directive studies had to set requirements for individual products where, in fact, it is the performance of the whole system that often needs to be optimised not just a single component or products.
The new directive will repeal the existing 2005/32/EC.
Aubrey de Grey now calls Actuarial Escape Velocity, the Methuselarity
A recent issue of Studies in Health Technology and Informatics includes a number of interesting papers on longevity science, or that relate to developing the tools and research community to enable engineered longevity. You might start with an essay by Aubrey de Grey, in which he coins a new term for an aspect what has in the past been called actuarial escape velocity – the point at which steadily increasing life expectancy rises by more than one year with each passing year:
Aging, being a composite of innumerable types of molecular and cellular decay, will be defeated incrementally. I have for some time predicted that this succession of advances will feature a threshold, which I here christen the ‘Methuselarity,’ following which there will actually be a progressive decline in the rate of improvement in our anti-aging technology that is required to prevent a rise in our risk of death from age-related causes as we become chronologically older. Various commentators have observed the similarity of this prediction to that made by Good, Vinge, Kurzweil and others concerning technology in general (and, in particular, computer technology), which they have termed the ‘singularity.’ In this essay I compare and contrast these two concepts.
At present, life expectancy is increasing at about one year for every five years that pass – only 20% of what is needed to keep our expected remaining years of life increasing at the same speed with which we age. That said, it is worth remembering that life expectancy is a statistical construct based on past data – it is a helpful measure of progress, but not necessarily an indication of where we are now. I suspect it lags present medical advances, for example, because their effects on mortality rate might not show up for a decade or more.
The Singularity and the Methuselarity: Similarities and Differences
Aging, being a composite of innumerable types of molecular and cellular decay, will be defeated incrementally. I have for some time predicted that this succession of advances will feature a threshold, which I here christen the “Methuselarity,” following which there will actually be a progressive decline in the rate of improvement in our anti-aging technology that is required to prevent a rise in our risk of death from age-related causes as we become chronologically older. Various commentators have observed the similarity of this prediction to that made by Good, Vinge, Kurzweil and others concerning technology in general (and, in particular, computer technology), which they have termed the “singularity.” In this essay I compare and contrast these two concepts.
Wikipedia on actuarial escape velocity.


